{"Clinical Trial ID": "NCT01901146", "Intervention": ["INTERVENTION 1:", "ABP 980", "Participants received PAP 980 at an initial dose of 8 mg/kg on a 90-minute intravenous (IV) infusion, followed by an IV infusion of 6 mg/kg every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m2 of paclitaxel Q3W for 4 cycles.", "INTERVENTION 2:", "- Trastuzumab", "Participants received trastuzumab at an initial dose of 8 mg/kg on a 90-minute IV infusion, followed by an IV infusion of 6 mg/kg Q3W for 3 additional cycles, plus 175 mg/m2 of paclitaxel Q3W for 4 cycles."], "Eligibility": ["Incorporation criteria:", "Women 18 years of age", "Invasive breast cancer confirmed histologically", "Planning the surgical resection of the breast tumour and the sentinel ganglion or the resection of the axillary lymph nodes", "Planning neoadjuvant chemotherapy", "HER2 positive disease", "A disease measurable in the breast after diagnostic biopsy, defined as the longest diameter 2.0 cm", "A known estrogen receptor (ER) and a known progesterone receptor (PR) at the start of the study", "Normal bone marrow function", "Normal liver function", "Normal renal function", "Subjects must sign an informed consent form approved by the Institutional Review Board/Ethics Board (CE/IRB) prior to any specific procedure under consideration.", "\u2022 Inclusion criteria for randomization:", "The left ventricular ejection fraction (LVEF) of 55% per 2D echocardiogram", "\u2022 Complete the 4 cycles of chemotherapy by rinsing", "- Exclusion criteria:", "Bilateral breast cancer", "Presence of known metastases", "Has received prior treatment, including chemotherapy, biological therapy, radiotherapy or surgery, except for primary breast cancer diagnostic biopsy", "Other concomitant active malignancy or history of malignancy in the last 5 years, with the exception of the treated basal cell carcinoma of the skin or in situ carcinoma of the cervix", "\u00b7 Clinically significant pre-existing peripheral neuropathy (grade 2)", "Any history of documented or current congestive heart failure, uncontrolled high-risk arrhythmias, current angina requiring medication, clinically significant valvular disease, current signs of transmural electrocardiogram infarction (ECG) or current poorly controlled hypertension", "\u2022 Severe resting dyspnoea requiring additional oxygen therapy", "\u2022 Positivity history for hepatitis B surface antigen, hepatitis C virus or human immunodeficiency virus (HIV)", "A recent infection requiring a series of systemic anti-infectives that were completed 14 days prior to registration (with the exception of an uncomplicated urinary infection)", "Women of childbearing potential who are pregnant or breastfeeding", "A woman of childbearing potential who does not consent to the use of highly effective contraceptive methods (e.g., actual abstinence (periodic abstinence (e.g., calendar ovulation, sympatothermic methods, post-ovulation) and withdrawal are not acceptable methods of contraception), sterilization or other non-hormonal forms of contraception) during treatment and for at least 7 months after the last administration of the protocol.", "In the course of treatment in another study of a research device or drug, or less than 30 days from the end of treatment in another study of a research device or drug", "Other investigation procedures when participating in this study are excluded", "The subject has a known sensitivity to one of the products to be administered during the study, including mammalian cell-derived drugs, trastuzumab, murine proteins or any of the excipients.", "The subject has already been registered and/or randomized in this study.", "Subject not available to complete all required protocols study visits or procedures", "A history or evidence of any other clinically significant disorder, condition or disease (except those described above) that, in the opinion of the investigator or Amgen physician, would pose a safety risk or interfere with the assessment, procedures or completion of the study."], "Results": ["Performance measures:", "Percentage of participants with a complete pathological response", "The complete pathological response (CPR) was defined as the absence of invasive tumour cells in breast tissue and axillary lymph nodes, regardless of the residual in situ channel carcinoma (CDIS).", "The participants underwent a mastectomy or mastectomy with sentinel lymph nodes dissection (DSL) or dissection of axillary lymph nodes (DSLL) within 3 to 7 weeks of the last dose of the drug studied in the neoadjuvant phase. The pathological evaluation of surgical samples for PCR analysis was carried out by local laboratories at the study sites.", "Time: 3 to 7 weeks after the last dose of the drug studied in the neoadjuvant phase", "Results 1:", "Title of arm/group: ABP 980", "The participants received PAP 980 at an initial dose of 8 mg/kg on a 90-minute intravenous (IV) infusion, followed by an IV infusion of 6 mg/kg every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m paclitaxel Q3W for 4 cycles.", "Total number of participants analysed: 358", "Type of measurement: Number", "Unit of measure: percentage of participants 48.0", "Results 2:", "Title of arm/group: Trastuzumab", "Description of the arm/group: Participants received trastuzumab at an initial dose of 8 mg/kg on a 90-minute IV infusion, followed by 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m paclitaxel Q3W for 4 cycles.", "Total number of participants analysed: 338", "Type of measurement: Number", "Unit of measure: percentage of participants 40.5"], "Adverse Events": ["Undesirable Events 1:", "Total: 18/364 (4.95%)", "Febrile neutropenia 3/364 (0.82%)", "Atrial fibrillation 1/364 (0.27%)", "Cardiorespiratory arrest 1/364 (0.27%)", "Sinus bradycardia 1/364 (0.27%)", "- Ventricular extrasystoles 0/364 (0.00 %)", "Enterocolitis 0/364 (0.00 %)", "- Fecaloma 0/364 (0.00 %)", "Gastric ulcer perforation 0/364 (0.00 %)", "Gastrointestinal toxicity 0/364 (0.00 %)", "- Acute Pancreatitis 0/364 (0.00 %)", "Adverse Events 2:", "Total: 5/361 (1.39 per cent)", "- Febrile neutropenia 0/361 (0.00 %)", "Atrial fibrillation 0/361 (0.00 %)", "Cardiorespiratory arrest 0/361 (0.00 %)", "Sinus bradycardia 0/361 (0.00 %)", "- Ventricular extrasystoles 0/361 (0.00 %)", "Enterocolitis 0/361 (0.00 %)", "- Fecaloma 0/361 (0.00 %)", "Gastric ulcer perforation 0/361 (0.00 %)", "gastrointestinal toxicity 1/361 (0.28%)", "- Acute Pancreatitis 0/361 (0.00 %)"]}